Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy

PURPOSE: The ICRU 89 recommends reporting a set of vaginal dose points for cervical cancer treatments in order to quantify the goodness of implant. This vaginal dose reporting method for combined external beam radiotherapy and brachytherapy has been adopted by the EMBRACE II study protocol. Large va...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrasco, Nuria, Chimeno, Jose, Adrià-Mora, Mar, Pérez-Calatayud, María José, Ibáñez, Blanca, Carmona, Vicente, Celada, Francisco, Gimeno, Jose, Lliso, Françoise, Pérez-Calatayud, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207226/
https://www.ncbi.nlm.nih.gov/pubmed/32395138
http://dx.doi.org/10.5114/jcb.2020.94494
_version_ 1783530557742776320
author Carrasco, Nuria
Chimeno, Jose
Adrià-Mora, Mar
Pérez-Calatayud, María José
Ibáñez, Blanca
Carmona, Vicente
Celada, Francisco
Gimeno, Jose
Lliso, Françoise
Pérez-Calatayud, José
author_facet Carrasco, Nuria
Chimeno, Jose
Adrià-Mora, Mar
Pérez-Calatayud, María José
Ibáñez, Blanca
Carmona, Vicente
Celada, Francisco
Gimeno, Jose
Lliso, Françoise
Pérez-Calatayud, José
author_sort Carrasco, Nuria
collection PubMed
description PURPOSE: The ICRU 89 recommends reporting a set of vaginal dose points for cervical cancer treatments in order to quantify the goodness of implant. This vaginal dose reporting method for combined external beam radiotherapy and brachytherapy has been adopted by the EMBRACE II study protocol. Large variations in dose between patients and centers have been reported. The aim of this study was to determine possible discrepancies with consensus observers from the same institution. Therefore, the inter- and intra-observer variability were analyzed. MATERIAL AND METHODS: For five patients, five experienced observers reported dose at the proposed vaginal points twice. The effect of inter- and intra-observer variations on total dose was analyzed by estimating biologically equivalent dose EQD(2) (α/β = 3 Gy). Coefficient of variation (CV) was used to provide a measure of data dispersion as a proportion to the mean. RESULTS: The maximum inter-observer deviation among all patients and all points ranged from 0.5 Gy to 24.1 Gy in EQD(2). The higher inter-observer discrepancies were found at points at 3 o’clock and at 6 o’clock, with respect to ovoids. In case of the maximum intra-observer deviation, it ranged from 0.5 Gy to 14.2 Gy, with higher deviation points at 12 o’clock and 9 o’clock, with respect to ovoids. CONCLUSIONS: There is a need to ensure consistency in vaginal points reporting. The impact of the dosimetric inter- and intra-observer variability should also be considered when dealing with dose tolerances and limits due to the potential dose gradient.
format Online
Article
Text
id pubmed-7207226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-72072262020-05-11 Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy Carrasco, Nuria Chimeno, Jose Adrià-Mora, Mar Pérez-Calatayud, María José Ibáñez, Blanca Carmona, Vicente Celada, Francisco Gimeno, Jose Lliso, Françoise Pérez-Calatayud, José J Contemp Brachytherapy Original Paper PURPOSE: The ICRU 89 recommends reporting a set of vaginal dose points for cervical cancer treatments in order to quantify the goodness of implant. This vaginal dose reporting method for combined external beam radiotherapy and brachytherapy has been adopted by the EMBRACE II study protocol. Large variations in dose between patients and centers have been reported. The aim of this study was to determine possible discrepancies with consensus observers from the same institution. Therefore, the inter- and intra-observer variability were analyzed. MATERIAL AND METHODS: For five patients, five experienced observers reported dose at the proposed vaginal points twice. The effect of inter- and intra-observer variations on total dose was analyzed by estimating biologically equivalent dose EQD(2) (α/β = 3 Gy). Coefficient of variation (CV) was used to provide a measure of data dispersion as a proportion to the mean. RESULTS: The maximum inter-observer deviation among all patients and all points ranged from 0.5 Gy to 24.1 Gy in EQD(2). The higher inter-observer discrepancies were found at points at 3 o’clock and at 6 o’clock, with respect to ovoids. In case of the maximum intra-observer deviation, it ranged from 0.5 Gy to 14.2 Gy, with higher deviation points at 12 o’clock and 9 o’clock, with respect to ovoids. CONCLUSIONS: There is a need to ensure consistency in vaginal points reporting. The impact of the dosimetric inter- and intra-observer variability should also be considered when dealing with dose tolerances and limits due to the potential dose gradient. Termedia Publishing House 2020-04-17 2020-04 /pmc/articles/PMC7207226/ /pubmed/32395138 http://dx.doi.org/10.5114/jcb.2020.94494 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Original Paper
Carrasco, Nuria
Chimeno, Jose
Adrià-Mora, Mar
Pérez-Calatayud, María José
Ibáñez, Blanca
Carmona, Vicente
Celada, Francisco
Gimeno, Jose
Lliso, Françoise
Pérez-Calatayud, José
Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title_full Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title_fullStr Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title_full_unstemmed Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title_short Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
title_sort inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207226/
https://www.ncbi.nlm.nih.gov/pubmed/32395138
http://dx.doi.org/10.5114/jcb.2020.94494
work_keys_str_mv AT carrasconuria interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT chimenojose interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT adriamoramar interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT perezcalatayudmariajose interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT ibanezblanca interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT carmonavicente interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT celadafrancisco interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT gimenojose interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT llisofrancoise interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy
AT perezcalatayudjose interobserverandintraobservervariabilityinreportingvaginaldosepointsforcervicalcancerinhighdoseratebrachytherapy